Q-omics provides the consensus-scored LPCAT3 profile across patient tissues and cancer cell-line models. LPCAT3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LPCAT3 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, LPCAT3 protein abundance shows 22,934 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, LUAD, and PDAC as cancer lineages where LPCAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LPCAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LPCAT3 survival associations across molecular data types. LPCAT3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LPCAT3 RNA expression–survival associations across cancer types. High LPCAT3 expression shows unfavorable associations in UVM, LAML, OV and LGG, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LPCAT3 RNA expression.
This table summarizes LPCAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LPCAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LPCAT3 shows lower tumor expression in LUAD, COAD and THCA and higher tumor expression in BLCA, KIRC and BRCA. The LUAD box plot shows higher LPCAT3 RNA expression in normal versus tumor tissue (log2 FC = −1.142, t-test p < 0.001).
This table shows molecular features associated with LPCAT3 in patient tissues and cancer cell lines. In patient samples, LPCAT3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, LPCAT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
